Filter by Category
Filter by Year

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

  • Kyowa Kirin expands the license agreement with one new ADC to a total of three ADC programs
  • Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC target
  • Decisions driven by highly competitive preclinical therapeutic index demonstrated by Kyowa Kirin’s lead program that was built by using Synaffix ADC technology
  • Triggers $5 million immediate payment to Synaffix and total potential payments for the first ADC program alone of up to $171m plus royalties on commercial sales

AMSTERDAM, NETHERLANDS – June 30, 2022  Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, has expanded the license agreement with Synaffix (announced in August 2021) by adding a third ADC target to its research evaluation and development efforts under this deal. In addition it exercised its option to take exclusive development and commercialization rights for an undisclosed ADC target under the terms of this agreement.

This follows a successful initial research collaboration between the companies whereby Kyowa Kirin has demonstrated a highly competitive preclinical therapeutic index for its lead program under this collaboration, prepared from a Kyowa Kirin antibody using Synaffix’s ADC technology.

The technology licensed from Synaffix include GlycoConnect™, HydraSpace™, and multiple toxSYN™ linker-payloads, which allow for the drug-to-antibody ratio (DAR) to be tailored to 1, 2 or 4 to optimize the therapeutic index of the ADC.

Under the terms of the amended license agreement, Synaffix will receive an immediate payment of $5 million and is eligible to receive total potential payments for the first ADC program alone of up to $171m plus royalties on commercial sales.  

Floris van Delft, Ph.D., Chief Scientific Officer of Synaffix, said:

We are thrilled with the successful ADC data, expansion of this license agreement and to see a leading global pharmaceutical company like Kyowa Kirin deploying Synaffix ADC technology in order to fulfill its mission of improving the lives of patients with cancer worldwide.

Join Mailing List

Copyright Synaffix BV 2021. All Rights Reserved

Protein Conjugates

Bring your own and/or choose from the following categories. 


Just like our ADC technology, we can easily attach peptide and protein-based payloads to your antibody.


Early preclinical data available on request.

Bring Your Own

scFv / Fab

Immune Cell Recruiters


T cell recruitment

NK cell recruitment

IL-15 Receptor Fusion

NK cell recruitment

HydraSpace™ Polar Spacer

Forming an integral part of every toxSYN™ linker-payload, HydraSpace™ bears a negative charge at physiological pH and improves:

  1. Therapeutic efficacy
  2. Tolerability
  3. PK
  4. Manufacturability
Key publication about HydraSpace

GlycoConnect™ design easily matches payload potency with the most appropriate drug-antibody ratio (DAR).

Key publications about GlycoConnect™

toxSYN™ Linker-Payloads

Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
Mode-of-Action Payload
(Active Catabolite)
1. SYNtecan E™*Topoisomerase inhibition Exatecan
2. SYNeamicin D™*DNA
Calicheamicin γ1I
3. SYNeamicin G™*N-glycyl calicheamicin γ1I
4. SYNstatin E™Microtubule
5. SYNstatin F™ MMAF
6. SYNtansine™ maytansinoid**

* Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace™

** N-6-aminohexanoyl-maytansine (Ahx-maytansine)